CD274 and non-small cell lung carcinoma: All 350 NSCLC patients in the MSKCC dataset received PD‐1/PD‐L1‐targeted monotherapy (atezolizumab, durvalumab, nivolumab, or pembrolizumab) or combination immunotherapy (Combo; 6%, 21/350).22